BACKGROUND: Activating, nonamplification ERBB2 mutations (ERBB2mut) are not detected by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH), but are detected by DNA sequencing and may predict clinical responses to human epidermal growth factor receptor (HER2)-targeted therapy. The authors queried 5605 advanced/metastatic breast cancers (mBC) to uncover the frequency of ERBB2mut genomic alterations. Clinical responses to anti-HER2 therapeutics were identified. METHODS: DNA was extracted from 40 µm of formalin-fixed paraffin-embedded (FFPE) sections. Comprehensive genomic profiling (CGP) was used to evaluate up to 315 genes (592× mean coverage depth). Results were analyzed for base substitutions, short indels, copy number changes, and selected rearrangements. RESULTS: Of 5605 cases, 698 (12.5%) featured ERBB2 alterations, including 596 (10.6%) ERBB2 amplifications (ERBB2amp) and 138 (2.4%) ERBB2mut; 38 cases (0.7%) had co-occurring ERBB2amp and ERBB2mut. ERBB2mut predominantly affected the kinase (124 cases; 90%) or extracellular (15 cases; 11%) domains. Both primary BC (52 cases; 38%) and metastatic site biopsies (86 cases; 62%) were found to harbor ERBB2mut, which were distributed across carcinoma not otherwise specified (NOS) (69 cases; 50%), invasive ductal carcinoma (IDC) (40 cases; 29%), invasive lobular carcinoma (ILC) (27 cases; 20%), and mucinous mBC (2 cases; 1%). Genes commonly coaltered with ERBB2 were tumor protein 53 (TP53) (49%); phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) (42%); cadherin 1, type 1 (CDH1) (37%); MYC (17%); and cyclin D1 protein (CCND1) (16%). CDH1 mutations were enriched in ERBB2mut mBC (P<0.0006) and associated with recurrent mBC. Selected patients with ERBB2mut, without ERBB2amp, who responded to anti-HER2 targeted therapies are presented herein. CONCLUSIONS: Within this large series, 1.8% of cases harbored ERBB2mut, which are undetectable by standard-of-care IHC or FISH tests. Metastatic BC driven by ERBB2mut respond to anti-HER2 targeted therapies, and expanding clinical trials designed to detect ERBB2mut by CGP and optimize targeted treatments are warranted. Cancer 2016.
BACKGROUND: Activating, nonamplification ERBB2 mutations (ERBB2mut) are not detected by immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH), but are detected by DNA sequencing and may predict clinical responses to humanepidermal growth factor receptor (HER2)-targeted therapy. The authors queried 5605 advanced/metastatic breast cancers (mBC) to uncover the frequency of ERBB2mut genomic alterations. Clinical responses to anti-HER2 therapeutics were identified. METHODS: DNA was extracted from 40 µm of formalin-fixed paraffin-embedded (FFPE) sections. Comprehensive genomic profiling (CGP) was used to evaluate up to 315 genes (592× mean coverage depth). Results were analyzed for base substitutions, short indels, copy number changes, and selected rearrangements. RESULTS: Of 5605 cases, 698 (12.5%) featured ERBB2 alterations, including 596 (10.6%) ERBB2 amplifications (ERBB2amp) and 138 (2.4%) ERBB2mut; 38 cases (0.7%) had co-occurring ERBB2amp and ERBB2mut. ERBB2mut predominantly affected the kinase (124 cases; 90%) or extracellular (15 cases; 11%) domains. Both primary BC (52 cases; 38%) and metastatic site biopsies (86 cases; 62%) were found to harbor ERBB2mut, which were distributed across carcinoma not otherwise specified (NOS) (69 cases; 50%), invasive ductal carcinoma (IDC) (40 cases; 29%), invasive lobular carcinoma (ILC) (27 cases; 20%), and mucinous mBC (2 cases; 1%). Genes commonly coaltered with ERBB2 were tumor protein 53 (TP53) (49%); phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) (42%); cadherin 1, type 1 (CDH1) (37%); MYC (17%); and cyclin D1 protein (CCND1) (16%). CDH1 mutations were enriched in ERBB2mut mBC (P<0.0006) and associated with recurrent mBC. Selected patients with ERBB2mut, without ERBB2amp, who responded to anti-HER2 targeted therapies are presented herein. CONCLUSIONS: Within this large series, 1.8% of cases harbored ERBB2mut, which are undetectable by standard-of-care IHC or FISH tests. Metastatic BC driven by ERBB2mut respond to anti-HER2 targeted therapies, and expanding clinical trials designed to detect ERBB2mut by CGP and optimize targeted treatments are warranted. Cancer 2016.
Authors: Lorenzo Gerratana; Andrew A Davis; Ami N Shah; Chenyu Lin; Carla Corvaja; Massimo Cristofanilli Journal: Curr Treat Options Oncol Date: 2019-06-29
Authors: Ariella B Hanker; Monica Red Brewer; Jonathan H Sheehan; James P Koch; Gregory R Sliwoski; Rebecca Nagy; Richard Lanman; Michael F Berger; David M Hyman; David B Solit; Jie He; Vincent Miller; Richard E Cutler; Alshad S Lalani; Darren Cross; Christine M Lovly; Jens Meiler; Carlos L Arteaga Journal: Cancer Discov Date: 2017-03-08 Impact factor: 39.397
Authors: Kanika Bajaj Pahuja; Thong T Nguyen; Bijay S Jaiswal; Kumar Prabhash; Tarjani M Thaker; Kate Senger; Subhra Chaudhuri; Noelyn M Kljavin; Aju Antony; Sameer Phalke; Prasanna Kumar; Marco Mravic; Eric W Stawiski; Derek Vargas; Steffen Durinck; Ravi Gupta; Arati Khanna-Gupta; Sally E Trabucco; Ethan S Sokol; Ryan J Hartmaier; Ashish Singh; Anuradha Chougule; Vaishakhi Trivedi; Amit Dutt; Vijay Patil; Amit Joshi; Vanita Noronha; James Ziai; Sripad D Banavali; Vedam Ramprasad; William F DeGrado; Raphael Bueno; Natalia Jura; Somasekar Seshagiri Journal: Cancer Cell Date: 2018-10-25 Impact factor: 31.743
Authors: Coren A Milbury; James Creeden; Wai-Ki Yip; David L Smith; Varun Pattani; Kristi Maxwell; Bethany Sawchyn; Ole Gjoerup; Wei Meng; Joel Skoletsky; Alvin D Concepcion; Yanhua Tang; Xiaobo Bai; Ninad Dewal; Pei Ma; Shannon T Bailey; James Thornton; Dean C Pavlick; Garrett M Frampton; Daniel Lieber; Jared White; Christine Burns; Christine Vietz Journal: PLoS One Date: 2022-03-16 Impact factor: 3.240
Authors: Liana Adam; F Anthony San Lucas; Richard Fowler; Yao Yu; Wenhui Wu; Yulun Liu; Huamin Wang; David Menter; Michael T Tetzlaff; Joe Ensor; Ganiraju Manyam; Stefan T Arold; Chad Huff; Scott Kopetz; Paul Scheet; Michael J Overman Journal: Clin Cancer Res Date: 2018-10-23 Impact factor: 12.531
Authors: Swapnil Parmar; Jamie M Keck; Ben Kong; Regan Look; Brett Johnson; Janice Patterson; Marilyne Labrie; Alexander R Guimaraes; Christopher L Corless; Carol Beadling; Annette Kolodzie; Raymond Bergan; Joe W Gray; Gordon B Mills; Zahi I Mitri Journal: JCO Precis Oncol Date: 2021-01-08